Skip to main content
EditionEnglish edition·Édition française
Investigation

Insulin: The Hundred-Year Ransom

Its inventors sold the patent for one dollar so no one would ever go without. A century later a vial costs $300 — and three companies collect the toll. The anatomy of the most defensible price in medicine, and the biosimilar cavalry riding to end it.

Key findings

  1. In 1923 the insulin patent was sold to the University of Toronto for $1 — so that, in the inventors' words, it would always be available to whoever needed it. University of Toronto archives; historical record
  2. A vial of insulin costs less than $10 to manufacture, yet uninsured American patients have paid over $300 for a single vial. Yale/MSF cost-of-production research; Ramapo News compilation, 2023
  3. Yale and Médecins Sans Frontières (JAMA Network Open, 2026) put cost-based biosimilar insulin at $61–$111 per year — against market prices of $98 to $1,300 per year across 13 countries. Newer analogs sell at 1.3 to 38.9 times their estimated cost-based price; the highest prices are in the United States. Barber et al., JAMA Network Open, 2026
  4. One in six American insulin users rations the drug. 16.5% of US insulin users reported rationing in 2021 — skipping doses of a medicine that keeps them alive. US National Health Interview Survey, 2021
  5. Three companies make almost all the world's insulin — Eli Lilly, Novo Nordisk and Sanofi — an oligopoly a century in the making. Industry and policy literature
  6. The cavalry is real. The FDA approved the first interchangeable biosimilar, Semglee (Mylan), in July 2021; Civica Rx committed to insulin at no more than $30 a vial; California committed $100 million to make its own biosimilar insulin. FDA, July 2021; Civica Rx, 2022; State of California, 2022
  7. The three chiefs: David Ricks (Eli Lilly), Lars Fruergaard Jørgensen (Novo Nordisk), Paul Hudson (Sanofi). Company disclosures, 2025–2026

They sold the cure for a dollar.

In 1921, in a Toronto laboratory, Frederick Banting and Charles Best isolated insulin — the hormone that turned a diagnosis of type 1 diabetes from a death sentence into a manageable condition. Two years later they sold the patent to the University of Toronto for one dollar. The intent is a matter of record: a drug this important should never be hostage to price. A century later, an uninsured American can be asked to pay more than $300 for a single vial — a vial that lasts about five days. That is more than $21,000 a year, for a molecule discovered before the television.

This investigation is about how a dollar's worth of generosity became a three-hundred-dollar toll booth: the three companies that hold the market, the arithmetic of the markup, and the biosimilar manufacturers now marching on the fortress.

The hundred-year toll booth

The market structure is the story's skeleton. Three companies — Eli Lilly of Indianapolis, Novo Nordisk of Denmark, and Sanofi of France — manufacture the overwhelming majority of the world's insulin. They did not arrive there by accident: a century of incremental patents (each small molecular tweak resetting the clock), a supply chain in which every intermediary takes a cut, and a product nobody can refuse — insulin is not optional for type 1 diabetics; without it, they die.

The cost arithmetic is now public. Yale postdoctoral researcher Melissa Barber, working with Médecins Sans Frontières, built the manufacturing cost of diabetes medicines from the ground up — active ingredient, formulation, devices, capital costs — and published the results in JAMA Network Open. Cost-based biosimilar insulin: $61 to $111 per year, with a profit margin already included. Annual market prices across 13 countries: $98 to $1,300. The newer insulin analogs sell at 1.3 to 38.9 times their estimated cost-based price, and the highest prices of all are in the United States — where the lowest prices were found in China, France, the Philippines and South Africa.

Chart 1 · The markup

What it costs vs. what it sells for

Insulin, annual cost per patient · Barber et al., JAMA Network Open 2026 (Yale / MSF)

Cost-based biosimilar$61–111/yrMarket: lowest country$98/yrMarket: United States$1,300/yrThe American patient pays up to 38.9 times the estimated cost-based price for insulin analogs.The French patient — in Sanofi's home country — pays among the lowest prices on earth.Same molecule. Same factories. The difference is the market structure.
A century-old molecule, sold at up to thirty-nine times its cost-based price in the richest country on earth. The inventors sold it for a dollar. Barber et al., JAMA Network Open 2026.

The human cost is not abstract. The 2021 National Health Interview Survey found that 16.5% of American insulin users ration their insulin — taking less than prescribed, stretching vials, risking hyperglycemia, kidney failure, blindness, death. Rationing insulin is rationing life, and one in six users does it. The endocrinologist quoted by the Indianapolis Business Journal put the supply-chain question plainly: the insulins are twenty years old, made the same way in the same factories — "what other manufactured product do you know that shows no economies of scale and no price drop in 20 years? TVs, phones, cars get cheaper — but insulin never does."

The three toll-keepers

The pyramid narrows to three desks. At Eli Lilly — the largest of the three, the company that first commercialized insulin a century ago — chief executive David Ricks presides over the American pricing machine. At Novo Nordisk, the Danish giant that grew from insulin into the obesity-drug colossus of the GLP-1 era, president and CEO Lars Fruergaard Jørgensen runs the world's diabetes franchise. At Sanofi — the French house whose Lantus was for years the world's leading basal insulin — CEO Paul Hudson holds the third seat. Three men, three countries, one shared position: the gatekeepers of a hormone two Canadians gave away for a dollar.

This correspondent writes from France — Sanofi's home — and names the French house's seat at the table without flinching. The Bureau's integrity rule cuts both ways: a correspondent calls out their own side when the ledger demands it. The ledger demands it here.

The biosimilar cavalry

For a century the fortress looked impregnable. It is not anymore. In July 2021, the FDA approved Semglee — Mylan's biosimilar of Lantus — as the first interchangeable insulin biosimilar: pharmacists could substitute it outright. Semglee launched at around $133 a vial against Lantus versions retailing above $300 — not cheap, but the first crack in the wall, and proof the wall could crack.

The second wave is institutional. The nonprofit Civica Rx announced in March 2022 it would manufacture three insulins — interchangeable with Lantus, Humalog and Novolog — and sell them for no more than $30 a vial, building its own plant in Petersburg, Virginia. The state of California went further: $50 million to develop biosimilar insulin products and another $50 million to build the manufacturing facility — a government making its own generic insulin. If a state can manufacture insulin at $30 a vial, the $300 vial has no defense left except habit.

Chart 2 · The siege

The price ladder is collapsing

Insulin vial price, $ · list and committed prices, 2021–2026

Brand analog (US list)$300+Semglee biosimilar~$133Civica Rx commitment≤$30Semglee: first interchangeable biosimilar, FDA July 2021. Civica Rx: nonprofit, $30 cap announced March 2022.California: $100M state program ($50M development + $50M facility), 2022.The ransom held for a century. The siege engines are built. The only question left is time.
From $300 to $30: the same molecule, three different centuries of pricing logic. The fortress is under siege from nonprofits and a state government. FDA 2021; Civica Rx 2022; State of California 2022; Medscape.

Banting sold it for a dollar. A century later, the toll is $300 a vial. The ransom is ending.

Where the record agrees — and where it argues

The consensus ledger below is the Bureau's hater-proofing. Everything printed above survived it; the disagreements are printed too.

  • Agreement: the 1923 patent sale to the University of Toronto for $1 is historical record.
  • Agreement: cost-based biosimilar insulin $61–$111/year vs. market $98–$1,300/year; analogs 1.3–38.9x cost-based; US prices highest (Barber et al., JAMA Network Open 2026).
  • Agreement: 16.5% of US insulin users rationed insulin in 2021 (NHIS).
  • Agreement: three firms dominate global insulin supply; Semglee approved as interchangeable biosimilar July 2021; Civica Rx $30/vial commitment; California $100M program.
  • Dispute: list price vs. net price — manufacturers argue rebates to middlemen (pharmacy benefit managers) mean the real price is far lower; critics reply that the uninsured patient pays the list price, and the patient is the one who rations.
  • Dispute: whether biosimilars will truly collapse prices — the first, Semglee, launched at ~$133, not $30; manufacturing scale takes years, and the incumbents' device and distribution moats are real.
  • Dispute: innovation credit — the industry argues a century of incremental improvements (analogs, pens, pumps) justifies the pricing; the Yale/MSF costing already includes device and development costs in its $61–$111 figure.

How this investigation was built

The Bureau's rule: every figure carries its source, and where sources disagree, both are printed.

  • Cost arithmetic from Barber et al., JAMA Network Open (Yale / Médecins Sans Frontières economic evaluation): cost-based biosimilar insulin $61–$111/year; market $98–$1,300/year across 13 countries; analogs 1.3–38.9x cost-based; US highest, China/France/Philippines/South Africa lowest.
  • Rationing from the US National Health Interview Survey, 2021 (16.5%).
  • History from the University of Toronto archives: Banting and Best, 1921 discovery; $1 patent sale, 1923.
  • The cavalry from the FDA (Semglee interchangeable approval, July 2021), Civica Rx (March 2022 announcement, ≤$30/vial, Petersburg VA plant), and the State of California ($50M + $50M, 2022).

The Bureau treats health as a factual subject: no mockery, no scorn — the numbers are indictment enough. When a state government builds its own insulin factory, the market has confessed.

Loading discussion…